← Back to Clinical Trials
Recruiting NCT07342361

NCT07342361 Using Retrograde Intrarenal Surgery for Managing Staghorn Renal Stones.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07342361
Status Recruiting
Phase
Sponsor Helwan University
Condition Renal Calculi
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2026-01-20
Primary Completion 2026-10-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Retrograde intrarenal surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2026-01-20 with a primary completion date of 2026-10-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective, randomized study is comparing the safety and efficacy of using two types of ureteral access sheaths in managing staghorn renal stones by retrograde intrarenal surgery.

Eligibility Criteria

Inclusion Criteria: * Adult patients of both sexes. * Patient has a staghorn renal stone (complete or partial staghorn). * Normal renal function tests. * Congenital renal anomalies as horseshoe, pelvic or mal-rotated kidneys. Exclusion Criteria: * Abnormal coagulation profile. * Active or untreated urinary tract infection. * Age under 18 years or above 70 years. * Patient has a staghorn stone associated with other pathology which requires additional intervention, as ureteral stricture or ureteropelvic junction obstruction (UPJO). * Pregnancy.

Contact & Investigator

Central Contact

Ahmed H Elsergany, MSc.

✉ dr_sergany2014@hotmail.com

📞 +20 1151405155

Principal Investigator

Ahmed H Elsergany, MSc

PRINCIPAL INVESTIGATOR

Helwan University

Frequently Asked Questions

Who can join the NCT07342361 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Renal Calculi. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07342361 currently recruiting?

Yes, NCT07342361 is actively recruiting participants. Contact the research team at dr_sergany2014@hotmail.com for enrollment information.

Where is the NCT07342361 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07342361 clinical trial?

NCT07342361 is sponsored by Helwan University. The principal investigator is Ahmed H Elsergany, MSc at Helwan University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology